Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
07:30am, Tuesday, 26'th May 2026
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40%
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
07:30am, Tuesday, 19'th May 2026
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Friday, 15'th May 2026
Plus Therapeutics (PSTV) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to a loss of $14 per share a year ago.
HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceu
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
11:39am, Thursday, 14'th May 2026
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.
Plenary session at AANS underscores REYOBIQ's potential as a differentiated targeted radiotherapeutic platform for CNS cancers Plenary session at AANS underscores REYOBIQ's potential as a differentiat
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
07:30am, Thursday, 07'th May 2026
HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiop
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
07:30am, Tuesday, 28'th Apr 2026
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in
HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radi
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 22'nd Apr 2026
HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceutica
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
07:30am, Tuesday, 21'st Apr 2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceutica
Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide adoption and long-term commercialization str
Plus Therapeutics Appoints Eric J. Daniels, M.D.
07:30am, Thursday, 09'th Apr 2026
Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-f
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
07:30am, Wednesday, 08'th Apr 2026
HOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pla
New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking New dedicated billing code facilitates payer reimbursement, supports
